Coronavirus Breaking News

The coronavirus disease COVID-19 is currently reaching pandemic levels in various countries.

Nov 11, 2020 • 2:34 pm CST

A limited, non-peer-reviewed study based on data provided by UK Biobank released on November 9, 2020, found (8) genetic variants significantly increase the risk of COVID-19 mortality among (45) patients with British ancestry.

The identified risk factors on Chromosomes 38 2, 6, 7, 8, 10, 16, and 17 contain genetic variants and genes related to cilia dysfunctions 39 (DNAH7 and CLUAP1), cardiovascular diseases, thromboembolic disease, mitochondrial dysfunctions, and innate immune system. DNAH7 has been reported recently as the most down-regulated gene after infecting human bronchial epithelial cells with the SARS-CoV2 coronavirus.

These researchers stated 'This new finding may provide evidence and clues for better understanding the molecular pathogenesis of COVID-19 and the genetic basis of heterogeneous susceptibility, with potential impact on therapeutic options for patients.'

The research was supported in part by the US National Institutes of Health.

Medical Review by
Nov 11, 2020 • 1:54 pm CST

Billboard.com exclusively reported on November 11, 2020, attending concert events in 2021 may require an attendee to disclose their personal health information to commercial companies.

The event ticket management firm Ticketmaster is reported to be working on a data management framework for post-COVID-19 pandemic fan safety that uses digital solutions to verify prospective fans' vaccination status or whether they've tested negative for the SARS-CoV-2 coronavirus within 72-hours.

Many of the details of this health privacy disclosure plan have not been finalized, reported Billboard.

Nov 11, 2020 • 10:06 am CST

The effectiveness of the Sputnik V vaccine candidate was found to be 92% based on the distribution of 20 confirmed cases identified in the placebo group and in the group receiving the vaccine candidate. And, the efficacy was proven based on the first interim data analysis 21-days after the study volunteers received their first immunization, reported NITsEM them. N.F. Gamaleis of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund, on November 11, 2020.

Currently, 20,000 volunteers are taking part in a Phase III, double-blind, randomized, placebo-controlled clinical trial of the Sputnik V vaccine and more than 16,000 volunteers have received the first and second doses of the vaccine candidate.

Alexander Gintsburg, Director of the N.N. N.F. Gamalei, stated in a press release: “Scaling up production and connecting new production sites will make the Sputnik V vaccine available to the general public. This will make it possible to reverse the current trend and achieve a decrease in the incidence of coronavirus infection, first in Russia, and then throughout the world."

Nov 11, 2020 • 7:57 am CST

New York-based Pfizer Inc. and its German partner BioNTech SE announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate to the European Union Member States. The vaccine deliveries are anticipated to start by the end of 2020, subject to clinical success and regulatory authorization.

According to the press statement on November 10, 2020, the European Commission has an option to purchase an additional 100 million BNT162b2 vaccine doses.

This mRNA SARS-CoV-2 coronavirus preventive vaccine candidate is in various late-stage clinical trials.

Nov 11, 2020 • 6:24 am CST

The U.S. FDA announced it will host a virtual FDA Grand Rounds: Facial Coverings During the COVID-19 Pandemic: How well do they flatten the curve?

This digital presentation scheduled for 12 ET on November 12, 2020, provides an overview of the FDA’s research to evaluate the ability of facial coverings to reduce the spread of infection and how the FDA is developing a comprehensive risk-assessment tool to predict the probability of infection with individuals wearing a non-surgical face mask or cloth face covering, given the characteristics of non-surgical face masks, the population, and the pathogen related to the SARS-CoV-2 coronavirus.

To register for the free webcast, please click this FDA link and then follow the instructions on the registration page.

Medical Review by
Nov 11, 2020 • 5:51 am CST

The U.S. CDC published a scientific briefing on November 10, 2020, which concluded 'experimental and epidemiological data support community masking to reduce the spread of the SARS-CoV-2 coronavirus. Multi-layer cloth masks have been found to both block up to 70% of fine droplets (10 microns) and limit the forward spread of those particles that are not captured.

The CDC says 'the relationship between source control and personal protection is likely complementary and possibly synergistic so that individual benefit increases with increasing community mask use.'

Note: none of the studies reviewed for this CDC briefing focused on the benefits or risks to a person when wearing a mask outside.

Nov 10, 2020 • 4:06 pm CST

According to a U.S. CDC report issued on November 6, 2020, adults who received positive test results for SARS-CoV-2 infection were more likely to report exclusively going to an office or school setting (aOR = 1.8, 95% CI = 1.2–2.7) in the 2-weeks before illness onset.

The Vanderbilt University Medical Center researchers suggest 'businesses and employers should promote alternative work-site options, such as teleworking, where possible, to reduce staff exposures to SARS-CoV-2.

Medical Review by
Nov 10, 2020 • 1:20 pm CST

The Russian Federation's capital city of Moscow's Mayor Sergei Sobyanin wrote on November 10, 2020, in an effort to reduce the spread of the SARS-CoV-2 virus that is causing COVID-19, restrictive measures would be extended from November 13, 2020, until January 15, 2021.

During this time frame, schoolchildren in Moscow will continue online, remote learning, reported TASS on November 10, 2020.

Nov 10, 2020 • 11:35 am CST

The University of Oxford announced it has joined forces with Thermo Fisher Scientific to ramp up the university’s capacity to deliver 50,000 COVID-19 tests per day. Announced on November 10, 2020, the new rapid testing laboratory and jointly developed Thermo Scientific OmnipathTM Combi SARS-CoV-2 IgG ELISA test detects and quantifies antibodies against the coronavirus.

Dr. Richard Cornall, Professor of Clinical Medicine and Head of the Nuffield Department of Medicine at the University of Oxford said in a press release, 'The collaboration is one of a number of projects that we’ve been co-developing with Thermo Fisher and is particularly important because it secures manufacturing and testing capacity that is important for the UK in the next phase of resolving the pandemic.'

Nov 10, 2020 • 11:26 am CST

The U.S. CDC reported about 156 million coronavirus diagnostic tests, excluding antibody, and antigen tests have been performed during 2020. Overall, these test results indicate a COVID-19 infection positivity rate of 7%, as of November 9, 2020.

The states of California (16,391,323), New York (15,191,030), Florida (12,244,769), and Texas (9,633,808) lead the USA's testing efforts.

And, as of November 9, 2020, the U.S. FDA had authorized 288 coronavirus diagnostic tests, which include 223 molecular tests, 58 antibody tests, and 7 antigen tests, since the COVID-19 pandemic began in early 2020.

Medical Review by
Nov 10, 2020 • 5:19 am CST

The Alaska Joint Base Elmendorf-Richardson (JBER) Commander Kristen Aguilar announced in a video on November 9, 2020, a Public Health Emergency that means the base is now under public health declaration due to the sustained community spread of the SARS-CoV-2 virus, which causes COVID-19.

As of November 9th, the U.S. Department of Defense reported (62,2477) coronavirus cases and (9) COVID-19 related fatalities during 2020.

Colonel Aguilar's 30-day declaration empowers base commanders to force quarantine and other restrictions of movement for anyone on base, according to the statement. JBER first imposed a public health declaration in March 2020, then in October, the commanders announced airmen and soldiers were to avoid Anchorage bars and in-restaurants dining.

Previously, Maj. Gen. Sean Bernabe, the 1st Armored Division commander at Fort Bliss, Texas, declared a public health emergency for his base on November 7, 2020.

Medical Review by
Nov 9, 2020 • 9:50 pm CST

Liverpool became the first city in England to roll out mass testing of its 496,000 population for COVID-19 under the UK's Operation Moonshot program, reported The BMJ on November 3, 2020. All people living or working in Liverpool will be offered COVID-19 tests regardless of whether they have symptoms.

Several types of covid tests will be used in the pilot, including existing polymerase chain reaction (PCR) swab tests, new lateral flow swab tests that can turn around results without the need to be processed in a laboratory, and new LAMP technology that will be deployed in Liverpool University Hospitals NHS Foundation Trust for NHS staff.

The pilot will test the feasibility of the government’s ambitious plans for mass population screening throughout England, as The BMJ first revealed in the leaked Operation Moonshot documents in September 2020. The UK Army will provide logistical support, with 2,000 personnel deployed.

Luke Allen, an academic clinical fellow at the University of Oxford, said in the BMJ article: “If it can be implemented smoothly then we will have a much clearer picture of how the virus is spreading. There are several big ‘ifs,’ though: people need to show up for testing, testing should happen repeatedly in order to track changes over time, and—most importantly—the track and trace system needs to function effectively.”

Nov 9, 2020 • 8:42 pm CST

Testing of Sinovac Biotech Ltd.’s COVID-19 vaccine candidate Coronavac has been halted in Brazil due to a serious adverse event reported Bloomberg on November 9, 2020. Brazil's Health Agency indicated the late-stage vaccine study was interrupted in accordance with local regulations.

The CoronaVac vaccine candidate is based on an inactivated pathogen made by growing the whole virus in a lab and then killing it, which is how polio shots are made.

Nov 9, 2020 • 8:21 pm CST

The Governor of Utah Gary R. Herbert declared a State of Emergency to address hospital overcrowding on November 8, 2020. Pursuant to the State of Emergency, the governor and Utah Department of Health have issued concurrent executive and public health orders designed to curb the surge of SARS-CoV-2 virus cases in Utah.

Under Utah's new public health order, all Utahns must wear masks in public, and when within 6-feet of anyone they don’t live with.

This mandate is also enforceable in business settings, which must require employees to wear masks, promote patrons to wear masks, and post signage to that effect. Businesses that fail to do so will be subject to fines.

Both orders became effective November 9th and will remain in effect until November 23, 2020. 'Please note that even after the 'orders' expire, the mask mandate will be extended for the foreseeable future,' added the Governor's press statement.

Nov 9, 2020 • 6:41 pm CST

The U.S. government stated on November 9, 2020, it will allocate 300,000 doses of Eli Lilly's Bamlanivimab to high-risk, COVID-19 patients, with no out-of-pocket costs for the medication.

This action follows the U.S. FDA granted Emergency Use Authorization for Bamlanivimab (LY-CoV555) 700 mg on November 9, 2020. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Lilly stated in a press release it will begin shipping Bamlanivimab immediately to a national distributor, which will distribute it as directed by the U.S. government's allocation program. Weekly allocation decisions will be proportionally based on confirmed COVID-19 cases in each state and territory over the previous seven days, based on data from the U.S. Department of Health and Human Services' Protect data collection platform.